Living with Alzheimer’s is often about More Than Just One Life
What is the GAP Study?
The Gammaglobulin Alzheimer's Partnership (GAP) Study is a clinical research study for people living with Alzheimer's, and for the many lives that may be affected by Alzheimer's disease in the future. It's a study for you, and for them – for now, and for the future.
This study is evaluating the effectiveness, safety, and tolerability of an investigational drug for Alzheimer's. The purpose of this study is to determine if this investigational drug may help slow the progression of Alzheimer's disease symptoms. The investigational drug (a form of Immune Globulin Intravenous called Gammaglobulin) has been approved by the FDA for use with other conditions; doctors and medical researchers are now evaluating its effectiveness, safety, and tolerability when it is used for Alzheimer's disease.
What is IVIg?
Researchers believe that Intravenous Immune Globulin (IVIg) may act on some of the underlying causes of Alzheimer's, instead of just on Alzheimer’s symptoms. In this study, IVIg will be evaluated alongside standard-of-care medications for Alzheimer's – so patients who participate will continue taking their current Alzheimer's medications.
IVIg (intravenous immune globulin) may also be known as "IGIV" (immune globulin intravenous) but generally both terms refer to the same therapy.